GitLab Inc. (GLAB)

About GitLab Inc.

Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company's products include LEGIO X COVID-19, a COVID-19 rapid antigen test; and LEGIO X Influenza AB, an influenza AB multiplex lateral flow test. It also develops respiratory syncytial virus and tuberculosis. Gemina Laboratories Ltd. was incorporated in 2017 and is headquartered in Burnaby, Canada.

Headquarters: Burnaby, BC · Website: https://www.geminalabs.com

Product categories

• Cloud Computing

Competitors of GitLab Inc.

• Alphabet Inc. (GOOGL)
• Apple Inc. (AAPL)
• MICROSOFT CORP (MSFT)
• AMAZON COM INC (AMZN)
• Meta Platforms, Inc. (META)
• Samsung Electronics Co., Ltd. (005930.KS)
• Tencent Holdings Limited (0700.HK)
• INTEL CORP (INTC)
• ORACLE CORP (ORCL)
• CISCO SYSTEMS, INC. (CSCO)
• NETFLIX INC (NFLX)
• Palantir Technologies Inc. (PLTR)

Frequently asked questions about GitLab Inc. (GLAB)

What is GitLab Inc. (GLAB)?

GitLab Inc. (GLAB) is a publicly traded company in the Healthcare sector (Biotechnology). Macroplane maps its supply-chain relationships, suppliers, buyers, financial health, and competitive positioning.

Who are GitLab Inc.'s main competitors?

Competitors of GitLab Inc. (GLAB) tracked by Macroplane include Alphabet Inc. (GOOGL), Apple Inc. (AAPL), MICROSOFT CORP (MSFT), AMAZON COM INC (AMZN), Meta Platforms, Inc. (META), Samsung Electronics Co., Ltd. (005930.KS), Tencent Holdings Limited (0700.HK), INTEL CORP (INTC), and 4 more.